Design and Rationale of a Real-Life Study to Compare Treatment Strategies for Cardiovascular Risk Factors: The CRUCIAL Study

References

• . Ezzati M, Hoorn SV, Lopez AD, . Comparative quantification of mortality and burden of disease attributable to selected risk factors. Chapter 4 in WHO 2006 Report: Global Burden of Disease and Risk Factors. http://www.dcp2.org/pubs/GBD Accessed December 16, 2009
   Google Scholar
• . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . Graham I, Atar D, Borch-Johnsen K, . European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28(19):2375–2414
   PubMed Web of Science ®Google Scholar
• . Conroy RM, Pyörälä K, Fitzgerald AP, ; SCORE project group.Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987–1003
   PubMed Web of Science ®Google Scholar
• . Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847
   PubMed Web of Science ®Google Scholar
• . Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16(2):121–137
   PubMedGoogle Scholar
• . Wong ND, Lopez V, Tang S, Williams GR. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204–208
   PubMed Web of Science ®Google Scholar
• . Benner JS, Smith TW, Petrilla AA, . Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States. J Am Soc Hypertens. 2008;2(1):44–53
   PubMed Web of Science ®Google Scholar
• . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, . Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–696
   PubMed Web of Science ®Google Scholar
• . Julius S, Kjeldsen SE, Weber M, ; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031
   PubMed Web of Science ®Google Scholar
• . Sever PS, Dahlöf B, Poulter NR, . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–1158
   PubMed Web of Science ®Google Scholar
• . Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004;25(6):484–491
   PubMed Web of Science ®Google Scholar
• . Ogedegbe G. Barriers to optimal hypertension control. J Clin Hypertens (Greenwich). 2008;10(8):644–646
   PubMed Web of Science ®Google Scholar
• . Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm. 2009;66(16):1471–1477
   PubMed Web of Science ®Google Scholar
• . Ho PM, Magid DJ, Shetterly SM, . Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772–779
   PubMed Web of Science ®Google Scholar
• . Agarwal S, Tang SS, Rosenberg N, . Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am J Ther. 2009;16(2):119–126
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Patel BV, Leslie RS, Thiebaud P, . Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008;4(3):673–681
   PubMedGoogle Scholar
• . McKeage K, Siddiqui MA. Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am J Cardiovasc Drugs. 2008;8(1):51–67
   PubMed Web of Science ®Google Scholar
• . Sever P, Dahlöf B, Poulter N, ; ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27(24):2982–2988
   PubMed Web of Science ®Google Scholar
• . Medical Research Council. MRC cluster randomized trials: methodological and ethical considerations. London, England: Medical Research Council; November 2002
   Google Scholar
• . Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES) 1999/2000. National Center for Health Statistics http://www.cdc.gov/nchs/nhanes.html. Accessed November 30, 2009
   Google Scholar
• . Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ. 2001;322(7282):355–357
   PubMed Web of Science ®Google Scholar
• . De Backer G, Ambrosioni E, Borch-Johnsen K, ; European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10(4):S1–S10
   PubMedGoogle Scholar
• . Park J. 2004 Korean Hypertension Treatment Guideline and Its Perspective. Korean Circ J. 2006;36(6):405–410
   Google Scholar
• . D'Agostino RB Sr, Vasan RS, Pencina MJ, . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753
   PubMed Web of Science ®Google Scholar
• . Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312–318
   PubMed Web of Science ®Google Scholar
• . Benner JS, Erhardt L, Flammer M, ; REACH OUT Investigators. A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile. Int J Clin Pract. 2008;62(10):1484–1498
   PubMed Web of Science ®Google Scholar
• . Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial. Circulation. 2009;119(15):2026–2031
   PubMed Web of Science ®Google Scholar
• . Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419–1423
   PubMed Web of Science ®Google Scholar